Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Gallium Components-Based Drug Delivery: A Potential Treatment for COVID-19

Author(s): Sara Torabi, Farbod Bahreini and Nima Rezaei*

Volume 22, Issue 3, 2022

Published on: 14 February, 2022

Article ID: e270122200590 Pages: 3

DOI: 10.2174/1871526522666220127120617

Abstract

With severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) showing new characteristics and manifesting new variants, the efficacy of vaccination can be reduced. In the meanwhile, no SARS-CoV-2-specific drug has been introduced in the fight against coronavirus disease 2019 (COVID-19) yet, and currently used drugs have also shown serious side effects in patients under treatment. Thus, it is pivotal to continue researching potential therapeutics to treat COVID-19. Recently, studies have shown that Gallium maltolate disrupts the replication of SARS-CoV-2 and therefore has antiviral activity against this virus. Nevertheless, as Gallium compounds have manifested serious side effects in the human body (e.g., hemoglobin synthesis dysfunction and pulmonary complications), drug delivery methods should be recruited to minimize the possible side effects and to optimize the efficacy of the drug in the fight against COVID-19. Liposomes, as nanocarriers, not only increase the half-life of the conjugated compound but also have shown promising features in the delivery of COVID-19-specific drugs to the target tissue. Herein, we propose that conjugation of Gallium maltolate with liposome nanocarriers can be beneficial to target tissues infected with SARS-CoV-2.

Keywords: SARS-CoV-2, COVID-19, liposomes, galium maltolate, nanoparticles, drug delivery.

Graphical Abstract

[1]
Bernstein LR, Zhang L. Gallium maltolate has in vitro antiviral activity against SARS-CoV-2 and is a potential treatment for COVID-19. Antivir Chem Chemother 2020; 28: 2040206620983780.
[http://dx.doi.org/10.1177/2040206620983780] [PMID: 33353394]
[2]
Chitambar CR. Medical applications and toxicities of gallium compounds. Int J Environ Res Public Health 2010; 7(5): 2337-61.
[http://dx.doi.org/10.3390/ijerph7052337] [PMID: 20623028]
[3]
Zamora E, Valdivia AY, Zalta B, Zuckier LS. [67Ga] Ga-citrate and COVID-19-associated pneumonia: An unexpected absence of uptake. Eur J Nucl Med Mol Imaging 2020; 47(9): 2207-8.
[http://dx.doi.org/10.1007/s00259-020-04886-9] [PMID: 32535654]
[4]
Krecic-Shepard ME, Shepard DR, Mullet D, Apseloff G, Weisbrode SE, Gerber N. Gallium nitrate suppresses the production of nitric oxide and liver damage in a murine model of LPS-induced septic shock. Life Sci 1999; 65(13): 1359-71.
[http://dx.doi.org/10.1016/S0024-3205(99)00375-6] [PMID: 10503955]
[5]
Torabi S, Bahreini F, Rezaei N. The role of angiotensin-converting enzyme 2 in COVID-19 induced lung injury. Acta Biomed 2020; 91(4): e2020142.
[PMID: 33525252]
[6]
Podsiadlo P, Komiyama T, Fuller RS, Blum O. Furin inhibition by compounds of copper and zinc. J Biol Chem 2004; 279(35): 36219-27.
[http://dx.doi.org/10.1074/jbc.M400338200] [PMID: 15140896]
[7]
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181(2): 271-80.
[8]
Kipshidze N, Iversen P, Porter TR, et al. Targeted, site-specific, delivery vehicles of therapeutics for COVID-19 patients. Brief review. Clin Appl Thromb Hemost 2020; 26: 1076029620954911.
[http://dx.doi.org/10.1177/1076029620954911] [PMID: 32936689]
[9]
Tai TT, Wu TJ, Wu HD, et al. A strategy to treat COVID-19 disease with targeted delivery of inhalable liposomal hydroxychloroquine: A preclinical pharmacokinetic study. Clin Transl Sci 2021; 14(1): 132-6.
[http://dx.doi.org/10.1111/cts.12923] [PMID: 33135382]
[10]
Mönkkönen J, Brown CS, Thompson TT, Heath TD. Liposome-mediated delivery of gallium to macrophage-like cells in vitro: demonstration of a transferrin-independent route for intracellular delivery of metal ions. Pharm Res 1993; 10(8): 1130-5.
[http://dx.doi.org/10.1023/A:1018955915848] [PMID: 8415397]
[11]
Makkonen N, Hirvonen M-R, Savolainen K, Lapinjoki S, Mönkkönen J. The effect of free gallium and gallium in liposomes on cytokine and nitric oxide secretion from macrophage-like cells in vitro. Inflamm Res 1995; 44(12): 523-8.
[http://dx.doi.org/10.1007/BF01757356] [PMID: 8788232]
[12]
Martins IJ, Redgrave TGA. 13CO2 breath test to assess the metabolism of triglyceride-rich lipoprotein remnants in mice. J Lipid Res 1998; 39(3): 691-8.
[http://dx.doi.org/10.1016/S0022-2275(20)33306-X] [PMID: 9548600]

Rights & Permissions Print Cite
Article Metrics
13
1
© 2024 Bentham Science Publishers | Privacy Policy